Mita,
"Not gaining market share as expected" was used to apply to any company in those circumstances.
The LIC analysts first predicted a fall in the ACR share price & were shorting well before the share price hit $4.77.
They may have experienced some short term pain but were proved right in the longer term.
At some stage a competitor could emerge with a superior product or the patent (I presume they have one) expires & others could market a generic product at a reduced price.
What then happens to the share price?
Companies who have one major product are susceptible to the above.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.366M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 883823 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 500697 | 1 |
View Market Depth
| Last trade - 16.21pm 30/07/2025 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable